This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Children with Crohn's disease are often malnourished at their initial diagnosis. Tumor necrosis factor-a (TNF-a) plays a pivotal role in Crohn's disease, as evidenced by increased serum TNF-a levels, intestinal TNF-a mRNA levels, and intestinal TNF-a secreting cells. Anti-tumor necrosis factor-a (anti-TNF-a) antibody (Infliximab) is an effective therapy for the induction and maintenance of clinical remission of Crohn's disease.
The aim of this study is to quantify changes in protein and lipid metabolism, resting energy expenditure, and albumin synthesis in children with Crohn's disease before and after treatment with anti-TNF-a antibody. We hypothesize that this treatment will decrease protein and lipid catabolism, decrease resting energy expenditure, and increase albumin synthesis. Our hypotheses will be tested by administering intravenous labeled amino acids in the fasting and intravenously fed states on the morning each child is scheduled to receive anti-TNF-a antibody. Serial blood draws will allow for analysis of rates of protein and albumin metabolism. Indirect respiratory calorimetry will be conducted at the end of the fasting and fed portions of the study for analysis of resting energy expenditure and lipid oxidation. The Pediatric Crohn's Disease Activity Index, including subjective report of symptoms, physical examination findings, and three laboratory examinations (hematocrit, erythrocyte sedimentation rate, and serum albumin), will be administered to each child during the visit. These children will then be studied in an identical manner two weeks later.
|Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592|
|Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201|
|Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445|
|Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048|
|Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461|
|Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668|
|Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610|
|Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:|
|Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527|
|Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419|
Showing the most recent 10 out of 767 publications